Angiotensin II vaccine: a novel approach in the treatment of hypertension.
BACKGROUND
Hypertension affects approximately 65 million Americans, resulting in 30 million office visits per year. Only about one third of patients have blood pressure below goal. Poor adherence to drug therapy is an important contributor to this statistic. An active immunization, which would induce antibodies against angiotensin, could simplify and improve treatment. An ideal regimen would be a few subcutaneous injections per year, which in turn could vastly improve adherence and subsequent outcomes.


OBJECTIVE
To discuss Cyt006-AngAb, a novel vaccine targeting angiotensin II, which is chemically linked to recombinant virus-like particles. Emphasis is placed on current progress of this vaccine's clinical trials.


METHODS
Relevant literature is discussed.


CONCLUSIONS
Although advances in hypertension vaccines have faced challenges, the angiotensin II vaccine may provide a promising approach in the control of hypertension.
Miller
Shannon A
SA
Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando Campus, 7975 Lake Underhill Road, Suite 200, Orlando, Florida 32822, USA. Shannon.miller@flhosp.org
Accardi
J Roger
JR
St Onge
Erin L
EL
D000328:Adult; D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000517:prevention & control* / Q000628:therapy*; D007114:Immunization; D008954:Models, Biological; D051381:Rats; D011994:Recombinant Proteins / Q000737:chemistry; D012084:Renin-Angiotensin System; D014611:Vaccination; D014612:Vaccines / Q000627:therapeutic use*
D011994:Recombinant Proteins; D014612:Vaccines; D000804:Angiotensin II